Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of MVA-NP+M1 in the influenza H3N2 human challenge model
2018-004015-49Phase 2Completed
- Sponsor
- Barinthus Biotherapeutics
- Start
- Jan 2019
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in influenza A H3N2 (H3N2) comparing MVA-NP+M1 with Saline placebo (2 arms). Primary endpoint: Total viral area under the curve (vAUC) for virologic shedding. Started Jan 2019; status: completed.
02
Drugs
VTP-100
03
Conditions
influenza A H3N2 (H3N2)
Beyond the preview
Go deeper on 2018-004015-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004015-49.